Jul 2026· International Journal of Molecular Sciences· Vol 27, pp. 6564· 0 citations· 59 references
Medicine
TL;DR
Results demonstrate that SNPH deficiency enhances the migration and metastatic potential of gastric cancer cells by driving EMT and invasion via the FAK/NF-κB/MMP-9 signaling pathway and propose that SNPH represents a novel biomarker and a promising therapeutic target for mitigating gastric cancer metastasis.
Abstract
Syntaphilin (SNPH), initially considered a neuron-specific protein, has recently been found to be widely expressed across various cancers. Mechanistically, SNPH inhibits mitochondrial transport to the cortical cytoskeleton, thereby suppressing cancer cell migration and metastasis. Although SNPH is known to participate in the metastatic progression of multiple malignancies, its precise underlying mechanism remains obscure. In this study, we investigated the role of SNPH in the epithelial–mesenchymal transition (EMT) and invasiveness of gastric cancer cells. Knockdown of SNPH in SNU-638 gastric cancer cells significantly enhanced their migratory and invasive capacities by approximately 1.4-fold and 2.5-fold, respectively. This knockdown concurrently increased focal adhesion kinase (FAK) phosphorylation, upregulated the EMT marker vimentin, and increased the expression of key EMT-related transcription factors, including Snail, Slug, and Twist. Furthermore, SNPH depletion induced the phosphorylation of nuclear factor kappa B (NF-κB), a transcription factor regulating matrix metalloproteinase-9 (MMP-9), which subsequently upregulated MMP-9 mRNA expression. This cascade promotes extracellular matrix degradation, thereby increasing metastatic potential. Notably, these phenotypic and molecular changes were completely reversed upon SNPH overexpression in SNU-638 cells. Taken together, our results demonstrate that SNPH deficiency enhances the migration and metastatic potential of gastric cancer cells by driving EMT and invasion via the FAK/NF-κB/MMP-9 signaling pathway. Consequently, we propose that SNPH represents a novel biomarker and a promising therapeutic target for mitigating gastric cancer metastasis.
Experimental data indicated that P4HA3 facilitated GC cell proliferation, migration and invasion, and enhanced glycolytic activity and increased the expression of key glycolysis-related proteins, suggesting that P4HA3 may induce a broader metabolic activation rather than an exclusively glycolytic shift.
Tao Wang· Pakistan Journal of Pharmace...· 0 citations
This study identifies SNX8 as a novel oncogenic regulator that promotes EMT and metastasis in HCC by stabilizing SMAD5 through the BMPR2 signaling axis and highlights the SNX8/SMAD5 axis as a potential therapeutic target for advanced HCC.
Xi-Hao Zhong, Yue-Kai Cui, Bing-Zi Zhu et al.· Journal of Translational Med...· 0 citations
Background Colorectal cancer (CRC) remains a major cause of cancer death worldwide, largely due to metastasis and drug resistance. The epithelial–mesenchymal transition (EMT) is known to drive CRC metastasis. ATM kinase has been reported to influence the Akt signaling pathway, which itself plays a central role in EMT....
Yu-Han Ding, Yuan Zhang, Zi-Heng Zhang et al.· Frontiers in Oncology· 0 citations
It is demonstrated that the m5C methyltransferase NSUN6 is significantly upregulated in EC tissues, and its expression correlates with higher tumor grade and unfavorable prognosis, and a proof‐of‐concept inhibitor, AL398, is provided, laying the groundwork for the development of first‐in‐class RNA methylation‐targeted...
Xiang-Zhuan Zhao, Lin-Lin Yang, Huanxiang Chen et al.· Advancement of science· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.